中国商报(记者 马嘉)美妆企业巨子生物近日发布的2024年年报显示,公司业绩实现高速增长。不过,仍有市场声音认为,重组胶原蛋白一直是巨子生物的“财富密码”,但是其已上市的化妆品技术门槛低、同质化竞争严重。而在门槛更高的医美行业,却迟迟不见巨子生物的动作。业绩大涨仍存隐忧根据巨子生物发布的财报,2024年,巨子生物营收达55.39亿元,同比增长57.2%;净利润达20.62亿元,同比增长42.1%。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.